Welcome to our dedicated page for CROSS COUNTRY HEALTHCARE SEC filings (Ticker: CCRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CROSS COUNTRY HEALTHCARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CROSS COUNTRY HEALTHCARE's regulatory disclosures and financial reporting.
Cross Country Healthcare, Inc. completed its previously announced merger with KL Criss Cross Merger Sub, Inc., an affiliate of Knox Lane, on July 21, 2026. Each share of Company common stock was converted into the right to receive $13.25 in cash per share, without interest and subject to withholding taxes. Outstanding restricted stock and performance stock awards were vested, canceled and cashed out based on the same $13.25 price, with performance awards settled at the greater of target or actual performance. Parent funded the transaction through a combination of cash on hand, including Company balance sheet cash, equity financing and debt financing, and the Company discharged all obligations under its ABL Credit Agreement dated October 25, 2019.
As of the merger’s effective time, Cross Country Healthcare became a wholly owned subsidiary of Parent, a change in control occurred, and holders of common stock ceased to have shareholder rights other than the right to receive the cash merger consideration. Trading in the Company’s shares on Nasdaq was suspended on July 21, 2026, with a Form 25 to remove the listing and an intended Form 15 to terminate registration and suspend SEC reporting. The pre-merger board members, including co‑founder and CEO Kevin C. Clark, resigned, and the directors and officers of Merger Sub assumed those roles. Joel Tremblay was appointed Chief Executive Officer, and the Company’s locums division was acquired by All Star Healthcare Solutions, a Knox Lane portfolio company.
Cross Country Healthcare, Inc. reported that Chief Accounting Officer Marvin Veizaga’s equity was settled in cash in connection with a merger in which the company became a wholly owned subsidiary of KL Criss Cross Intermediate, LLC. On 2026-07-21 he disposed of 31480 shares of common stock to the issuer at $13.25 per share, while performance-based restricted stock awards covering 16797 shares first vested at target and were then cancelled for the same cash merger consideration.
Cross Country Healthcare Chief Operating Officer Amiee Lin Hawkins reported equity changes tied to a cash merger. At the merger’s effective time, 43,953 common shares and 27,897 performance-based restricted stock awards were disposed of to the issuer and converted into the right to receive $13.25 in cash per share.
Cross Country Healthcare executive Marc S. Krug reported share-based transactions tied to a merger in which each share of common stock was converted into the right to receive $13.25 in cash. Outstanding restricted and performance-based stock awards vested, were cancelled, and converted into equivalent cash rights at that merger consideration.
Susan E. Ball, General Counsel and Secretary of Cross Country Healthcare, reported Form 4 transactions tied to the closing of a merger in which the company became a wholly owned subsidiary of KL Criss Cross Intermediate. At the merger’s Effective Time, each share of common stock converted into the right to receive $13.25 in cash.
In connection with this, she reported issuer dispositions of 241,777 and 72,872 shares of common stock at $13.25 per share, reflecting conversion of common and restricted stock into cash consideration. She also reported the vesting, at target, of a 72,872‑share performance-based restricted stock award, which was then cancelled and cashed out at the merger price.
Cross Country Healthcare Inc. Chief Financial Officer William J. Burns reported equity changes in connection with a merger in which the company became a wholly owned subsidiary of KL Criss Cross Intermediate, LLC. At the merger’s Effective Time, 336,438 common shares and 104,157 shares underlying performance-based restricted stock awards were disposed to the issuer, each automatically converted into the right to receive $13.25 in cash per share. The 104,157 performance-based awards first vested at target levels and were recorded as an acquisition at no cost before being cancelled for the same cash consideration.
Cross Country Healthcare Chief Executive Officer Clark Kevin Cronin reported merger-related equity transactions on July 21, 2026. In connection with the company’s acquisition by KL Criss Cross Intermediate, his common and restricted shares, including performance-based awards and shares held by his spouse, were converted and disposed to the issuer for $13.25 per share in cash merger consideration.
Cross Country Healthcare Inc director Janice Elizabeth Nevin reported a disposition of 48,616 shares of common stock on 2026-07-21. These shares were automatically converted into the right to receive $13.25 in cash per share at the effective time of a merger, leaving her with no reported holdings of this stock.